Thu. 23 May 2024, 2:17am ET
Benzinga
News
The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $500 million. The offering is expected to close on May 28, 2024, subject to customary closing conditions